| Name | Title | Contact Details |
|---|
The Argen Corporation is the world`s largest manufacturer of precious dental gold alloys, leader in zirconia manufacturing, and leading innovator of digital dentistry solutions and scrap refining services. With more than 50 years serving the dental industry, Argen now distributes to more than 100 countries with subsidiaries in Canada, China, Germany and the United Kingdom. Argen enables dental labs of all sizes to integrate digital into every aspect of their workflow by offering a wide range of digitally-produced products and services. Argen is proud to be a family-owned American company that manufactures the highest quality products in the US and is dedicated to treating customers like family.
If you suffer from chronic pain or aching in your knee, you may have osteoarthritis (OA) – a painful joint condition that can interfere with nearly all aspects of daily life. Right now, doctors at select centers in the U.S. are accepting participants for the Atlas Clinical Trial. The trial is for the Atlas System – an investigational device designed to relieve knee pain, while preserving your joint’s natural anatomy and motion.
The company is focused on establishing a new standard of care for women with symptomatic uterine fibroids. The Acessa System is cleared by the FDA and has CE mark for use in percutaneous, laparoscopic coagulation and ablation of soft tissue, including treatment of symptomatic uterine fibroids under laparoscopic ultrasound guidance. The Company is located in Austin, TX.
We are a medical technology company developing next-generation solutions for the treatment of chronic venous insufficiency, a progressive medical condition affecting an estimated 10% of adults.
NeuroOne Medical Technologies Incorporated (Ticker: NMTC) is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, initially targeting epilepsy. Today, our attention is on the development and commercialization of patented thin-film, cortical electrode technology for intracranial electroencephalography (iEEG) and depth electrodes for stereoelectroencephalography (sEEG) recording of brain activity. The products currently available in these categories have significant limitations such as low recording resolution and high risk of infection. NeuroOne believes our technology can address these unmet needs upon initial commercialization with pipeline technology to advance the field by enabling minimally invasive techniques and all-in-one diagnostic and therapeutic options. While our initial focus is Epilepsy, future applications in Parkinson`s disease, Essential tremors, and Dystonia are within sight. NeuroOne technologies will be presented to a well-defined market, eager for the advancement they bring. There are 188 hospital centers licensed to perform epilepsy surgical procedures in the U.S. The current addressable market opportunity for is approximately $525.6 million. As more patients choose the minimally invasive procedures made available by NeuroOne technology, the future opportunity is estimated to be approximately $14.9 billion with full market penetration.